1-(4-(4-hydroxyphenyl)piperazin-1-yl)ethanone profile

1-(4-(4-hydroxyphenyl)piperazin-1-yl)ethanone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	712441
CHEMBL ID	202608
SCHEMBL ID	1128293
MeSH ID	M0585375

Synonym
SDCCGMLS-0066236.P001
1-acetyl-4-(4-hydroxyphenyl)piperazine
OPREA1_786576
1-[4-(4-hydroxyphenyl)piperazin-1-yl]ethanone
STK428757
1-acetyl-4-(4-hydroxyphenyl)piperazine, 98%
AC-11753
67914-60-7
4-(4-acetyl-1-piperazinyl)phenol
CHEMBL202608
AKOS000120546
4-(4-tert-butylphenyl)-2-(1-methylindol-3-yl)-4-oxo-butanoic acid
A835934
4-(1-acetylpiperazin-4-yl)phenol
1-acetyl-4-(4-hydroxyphenyl)-piperazine
yh9gd5k5ny ,
einecs 267-744-8
unii-yh9gd5k5ny
ethanone, 1-[4-(3-hydroxyphenyl)-1-piperazinyl]-
FT-0607282
1-(4-(4-hydroxyphenyl)piperazin-1-yl)ethan-1-one
4-acetyl-1-(4-hydroxyphenyl)piperazine
1-acetyl-4-(4-hydroxyphenyl) piperazine
1-(4-(4-hydroxyphenyl)piperazin-1-yl)ethanone
1-[4-(4-hydroxyphenyl)-piperazin-1-yl]-ethanone
1-acetyl-4-(4-hydroxyphenyl)-piperizine
4-(4-acetylpiperazin-1-yl)phenol
4-(4-hydroxy-phenyl)-1-acetylpiperazine
4-(4-hydroxyphenyl)-1-acetylpiperazine
tox21_113834
dtxcid1031593
4-(4-acetylpiperazin-4-yl)phenol
cas-67914-60-7
NCGC00253715-01
dtxsid3057804 ,
SCHEMBL1128293
piperazine, 1-acetyl-4-(4-hydroxyphenyl)-
n-acetyl-4-(4-hydroxyphenyl)piperazine
W-104695
1-acetyl-4-(4-hydroxylphenyl)piperazine
mfcd00044905
F0001-1784
sr-01000944777
SR-01000944777-1
Z28269747
1-acetyl-4-(4'-hydroxyphenyl)piperazine
1-[4-(4-hydroxyphenyl)piperazin-1-yl]ethan-1-one
4-(4-acetyl-1-piperazino)phenol
E70355
FS-4259
ethanone, 1-(4-(4-hydroxyphenyl)-1-piperazinyl)-
1-(4-(4-hydroxyphenyl)-1-piperazinyl)ethanone
AMY3594
Q27455472
ethanone,1-[4-(3-hydroxyphenyl)-1-piperazinyl]-
EN300-15549
CS-W014753

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	29.8493	0.0060	38.0041	19,952.5996	AID1159521
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	2.9849	0.0010	22.6508	76.6163	AID1224838
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	9.7717	0.0123	7.9835	43.2770	AID1645841
cytochrome P450 2D6	Homo sapiens (human)	Potency	13.8029	0.0010	8.3798	61.1304	AID1645840
vitamin D (1,25- dihydroxyvitamin D3) receptor	Homo sapiens (human)	Potency	13.3322	0.0237	23.2282	63.5986	AID743222
Histone H2A.x	Cricetulus griseus (Chinese hamster)	Potency	27.1578	0.0391	47.5451	146.8240	AID1224845; AID1224896
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	33.4889	0.0006	27.2152	1,122.0200	AID743202; AID743219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (41)

Assay ID	Title	Year	Journal	Article
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID260487	Inhibition of large conductance calcium-activated potassium channel in bovine smooth muscle cells at 30 uM	2006	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4	Partial structures of ketoconazole as modulators of the large conductance calcium-activated potassium channel (BK(Ca)).
AID260489	Opening of large conductance calcium-activated potassium channel in bovine smooth muscle cells at 10 uM	2006	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4	Partial structures of ketoconazole as modulators of the large conductance calcium-activated potassium channel (BK(Ca)).
AID260492	Functional activity at large conductance calcium-activated potassium channel in bovine smooth muscle cells	2006	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4	Partial structures of ketoconazole as modulators of the large conductance calcium-activated potassium channel (BK(Ca)).
AID260490	Opening large conductance calcium-activated potassium channel in bovine smooth muscle cells at 30 uM	2006	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4	Partial structures of ketoconazole as modulators of the large conductance calcium-activated potassium channel (BK(Ca)).
AID1810699	Agonist activity at full length TLX activating element expressed in human HEK293T cells coexpressing human full-length TLX/Gal4-VP 16 assessed as fold increase in reporter activity at 100 uM by luciferase reporter gene assay relative to control	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Propranolol Activates the Orphan Nuclear Receptor TLX to Counteract Proliferation and Migration of Glioblastoma Cells.
AID260491	Opening large conductance calcium-activated potassium channel in bovine smooth muscle cells at 100 uM	2006	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4	Partial structures of ketoconazole as modulators of the large conductance calcium-activated potassium channel (BK(Ca)).
AID1810680	Stabilization of human recombinant TLX LBD assessed as change in melting temperature at 500 uM by DSF assay	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Propranolol Activates the Orphan Nuclear Receptor TLX to Counteract Proliferation and Migration of Glioblastoma Cells.
AID260488	Inhibition of large conductance calcium-activated potassium channel in bovine smooth muscle cells at 100 uM	2006	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4	Partial structures of ketoconazole as modulators of the large conductance calcium-activated potassium channel (BK(Ca)).
AID1810678	Agonist activity at in human TLX LBD expressed in human HEK293T cells coexpressing Gal4-VP 16 assessed as fold decrease in reporter activity at 100 uM measured after 14 hrs by luciferase reporter gene assay relative to control	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Propranolol Activates the Orphan Nuclear Receptor TLX to Counteract Proliferation and Migration of Glioblastoma Cells.
AID260486	Inhibition of large conductance calcium-activated potassium channel in bovine smooth muscle cells at 10 uM	2006	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4	Partial structures of ketoconazole as modulators of the large conductance calcium-activated potassium channel (BK(Ca)).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (8.33)	29.6817
2010's	4 (33.33)	24.3611
2020's	7 (58.33)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	12 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
nitrates Nitrates: Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical.	2.11	1	monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species
acetaminophen Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.	2.11	1	acetamides; phenols	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; cyclooxygenase 3 inhibitor; environmental contaminant; ferroptosis inducer; geroprotector; hepatotoxic agent; human blood serum metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
atenolol Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.. atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.	2.31	1	ethanolamines; monocarboxylic acid amide; propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; sympatholytic agent; xenobiotic
ketoconazole 1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.	2.03	1	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine
propafenone Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.. propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.	2.31	1	aromatic ketone; secondary alcohol; secondary amino compound	anti-arrhythmia drug
propranolol Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.	2.31	1	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
sotalol Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.. sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.	2.31	1	ethanolamines; secondary alcohol; secondary amino compound; sulfonamide	anti-arrhythmia drug; beta-adrenergic antagonist; environmental contaminant; xenobiotic
norchlorcyclizine norchlorcyclizine: RN given refers to parent cpd	2.31	1
2-hydroxyacetanilide 2-acetamidophenol : A member of the class of phenols that is 2-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group. A positional isomer of paracetamol which possesses anti-inflammatory, anti-arthritic and anti-platelet aggregation properties.	2.11	1	acetamides; phenols	anti-inflammatory agent; antineoplastic agent; antirheumatic drug; apoptosis inducer; platelet aggregation inhibitor; xenobiotic metabolite
dexpropranolol [no description available]	2.31	1	propranolol
1-methylxanthine 1-methylxanthine: urinary metabolite of caffeine. 1-methylxanthine : A monomethylxanthine having the methyl group located at the 1-position. It is a metabolite of caffeine in humans.. 1-methyl-7H-xanthine : A 1-methylxanthine tautomer where the imidazole proton is located at the 7-position.	2.31	1	1-methylxanthine	mouse metabolite
tryptoline tryptoline: neurotoxic factor that may be involved in development of Parkinson's disease; enzymatic prep from human brain converts tryptamine to tryptoline; RN given refers to parent cpd; structure	2.31	1	beta-carbolines
tadalafil [no description available]	2.31	1	benzodioxoles; pyrazinopyridoindole	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
n-desisopropylpropranolol N-desisopropylpropranolol: RN given refers to parent cpd	2.31	1
2-aminoquinoxaline 2-aminoquinoxaline: structure in first source	2.31	1

Condition	Relationship Strength	Studies
Congenital Zika Syndrome [description not available]	2.25	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.25	1
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1
Astrocytoma, Grade IV [description not available]	2.31	1
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	2.31	1

1-(4-(4-hydroxyphenyl)piperazin-1-yl)ethanone

Description

Cross-References

Synonyms (57)

Protein Targets (7)

Potency Measurements

Bioassays (41)

Research

Studies (12)

Market Indicators

Research Demand Index: 13.00

Study Types

1-(4-(4-hydroxyphenyl)piperazin-1-yl)ethanone

Description

Cross-References

Synonyms (57)

Protein Targets (7)

Potency Measurements

Bioassays (41)

Research

Studies (12)

Market Indicators

Research Demand Index: 13.00

Study Types

Related Drugs (15)

Related Conditions (5)